Navigation Links
Savient Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
Date:8/6/2012

EAST BRUNSWICK, N.J., Aug. 6, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Lou Ferrari, President and Chief Executive Officer, will present at the Canaccord Genuity 32nd Annual Growth Conference on Thursday, August 16, 2012 at 1:00 PM Eastern Time.  The conference will be held at the InterContinental Hotel in Boston, MA.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT – GContact:Mary ColemanCarney Noensie
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals Adopts Stockholder Rights Plan
2. Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation
3. Savient Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call on Wednesday, August 8, 2012
4. Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
5. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
6. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
7. TWi Pharmaceuticals Announces Positive Phase IIb Clinical Trial Results of AC-201 in Patients with Type 2 Diabetes.
8. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
9. Cumberland Pharmaceuticals Reports Second Quarter 2012 Financial Results
10. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
11. Global Pharmaceuticals Market 2011-2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ... size less than 10 bps, yet are surprisingly capable ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence ... a Medical Fitness Center by the Medical Fitness ... and fitness centers to achieve their full potential. ... only certified fitness center in the western suburbs ... "The certification means the Cadence Fitness & Health ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... market research report is available in its ... Market & Forecast – Worldwide Analysis ... Insulin Pump Market Analysis ... in the market as insulin delivery systems ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... data,supporting the clinical development of telaprevir (VX-950), one ... the,treatment of hepatitis C virus (HCV) infection, will ... European Association for the,Study of the Liver (EASL) ... to telaprevir have been accepted for presentation,at the ...
... meeting of the European,Association for the Study of ... /PRNewswire-FirstCall/ --,Schering-Plough Corporation reaffirms its commitment to advancing,the ... (HCV),infection with several key data presentations at the ... 42nd annual meeting,in Barcelona, Spain, April 11-15. A ...
Cached Medicine Technology:Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 2Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 3Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 5Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 6Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 2Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 3Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 4Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 5Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 6Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 7
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... RESULTS, EUR,000,000 2008 ... 92.5 99.3 EBITDA* ... 14.0% 16.1% Current operating income* ... (2.8) (2.7) Net income ...
... central nervous system , , WEDNESDAY, July 30 (HealthDay News) ... depression, at least in mice. , According to the ... Istvan Mody, both of the David Geffen School of ... of a particular class of proteins called GABA receptors ...
... Data from 260 hospitals across the United States has ... to more accurately determine the severity of heart failure in ... mortality and more quickly identifying triage methods and treatment decisions. ... the Journal of the American College of Cardiology . ...
... for Universal, Health Coverage Proposal but Obstacles Remain, According ... ... 30 ,HealthLeaders-InterStudy, a leading provider of managed care market,intelligence, reports ... windfall for the state of New Mexico has resulted in ...
... recently,submitted its bid to the U.S. Department of ... third generation TRICARE South Region contract. If,awarded the ... active,duty, retired and participating reserve and National Guard ... on April 1, 2010., "It is TriServ,s ...
... Sunrise Senior Living,Inc. (NYSE: SRZ ) today ... and webcast to discuss the Company,s 2007 financial ... data.,The call will now be held on Friday, ... will issue its 2007 financial results and second-quarter ...
Cached Medicine News:Health News:PCAS : Half Result 2008 2Health News:Possible Cause of Postpartum Depression Pinpointed 2Health News:Possible Cause of Postpartum Depression Pinpointed 3Health News:New method assesses risks for heart failure patients 2Health News:Gov. Richardson's Healthcare Reform Agenda Gains New Life 2Health News:Sunrise Updates Date and Time of Conference Call to Discuss 2007 Financial Results and Second-Quarter 2008 Preliminary Selected Financial and Operating Data 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: